NICE reccomends additional treatment for patients with ankylosing spondylitis.
The National Institute for Health and Care Excellence (NICE) has, in its guidelines, recommended Simponi (golimumab) from Merck Inc., as a treatment for ankylosing spondylitis in adults whose disease has responded inadequately to Non-steroidal anti-inflammatory drugs (NSAIDS) or adults who cannot tolerate NSAIDS. NICE has recommended, in the past, Humira (adalimumab), Enbrel ( etanercept) and Cimzia (certolizumab pegol) for the condition and has stipulated that the cheapest of these therapies will be selected to treat the condition .
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.